REVERSAL Trial: Difference between revisions
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==REVERSAL Trial== ===Objective=== To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and ...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and progression by intensive lipid lowering. | To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and progression by intensive lipid lowering. | ||
==Methods== | |||
Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] was a multicentered, randomized, double- blinded trial wherein 654 patients received the study drug. IVUS examinations were performed at baseline and after 18 months of treatment in 502 patients. Patients randomly received either 40 mg pravastatin or 80 mg of atorvastatin. | Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] was a multicentered, randomized, double- blinded trial wherein 654 patients received the study drug. IVUS examinations were performed at baseline and after 18 months of treatment in 502 patients. Patients randomly received either 40 mg pravastatin or 80 mg of atorvastatin. | ||
==Results== | |||
The mean LDL-C levels reduced from 150 to 110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin. Percentage change in atheroma volume showed a significantly lower progression rate in the atorvastatin (intensive) group compared to the pravastatin group. | The mean LDL-C levels reduced from 150 to 110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin. Percentage change in atheroma volume showed a significantly lower progression rate in the atorvastatin (intensive) group compared to the pravastatin group. | ||
==Conclusion== | |||
In patients with coronary artery disease, [[atorvastatin]] reduced progression of coronary atherosclerosis compared with [[pravastatin]].<ref name="urlEffect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI">{{cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/14996776?dopt=Abstract |title=Effect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI |format= |work= |accessdate=}}</ref> | In patients with coronary artery disease, [[atorvastatin]] reduced progression of coronary atherosclerosis compared with [[pravastatin]].<ref name="urlEffect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI">{{cite web |url=http://www.ncbi.nlm.nih.gov/pubmed/14996776?dopt=Abstract |title=Effect of intensive compared with moderate lipid-loweri... [JAMA. 2004] - PubMed - NCBI |format= |work= |accessdate=}}</ref> | ||
Latest revision as of 23:22, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
REVERSAL Trial On the Web |
|
American Roentgen Ray Society Images of REVERSAL Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To compare the effects of pravastatin and atorvastatin on coronary artery plaque burden and progression by intensive lipid lowering.
Methods
Reversal of Atherosclerosis with Aggressive Lipid Lowering [REVERSAL] was a multicentered, randomized, double- blinded trial wherein 654 patients received the study drug. IVUS examinations were performed at baseline and after 18 months of treatment in 502 patients. Patients randomly received either 40 mg pravastatin or 80 mg of atorvastatin.
Results
The mean LDL-C levels reduced from 150 to 110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin. Percentage change in atheroma volume showed a significantly lower progression rate in the atorvastatin (intensive) group compared to the pravastatin group.
Conclusion
In patients with coronary artery disease, atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin.[1]